# BOSTON (NCT03110562)

> Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03110562
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Karyopharm Therapeutics Inc
- Conditions: Multiple Myeloma
- Interventions: Selinexor; Bortezomib; Dexamethasone
- Enrollment: 402
- Primary outcome: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)

## Indexed commentary on BOSTON so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=boston-nct03110562
